# What 869 trials say about diabetes drugs > A living BMJ review maps the benefits and harms of 63 drugs, showing why heart, kidney and weight priorities matter more than a single league table. _Source: BMJ living systematic review and network meta-analysis, cross-checked with PubMed/Europe PMC and Crossref · 2026-08-27 · 7 min read · Verified against primary sources_ Canonical: https://iyu.app/e/type-2-diabetes-drug-evidence-2025 ## The 60-second version A living BMJ review of 869 randomized trials shows that type 2 diabetes medicines have different strengths and harms, so treatment choice should follow a person's risk profile and priorities. **Key points** - SGLT-2 inhibitors and GLP-1 receptor agonists have established cardiovascular and kidney benefits, while finerenone benefits selected patients with chronic kidney disease. - Tirzepatide produced the largest average weight reduction in the network, but weight is only one outcome and gastrointestinal harms matter. - Network meta-analysis mixes direct and indirect comparisons, and absolute benefits depend strongly on baseline risk. - Drug-specific harms include genital infection, ketoacidosis, gastrointestinal events, hyperkalaemia, fracture, heart-failure hospitalization and hypoglycaemia. **Verdict.** Use the evidence to structure a clinician conversation, not to self-prescribe or chase a universal winner. ## Full explainer ### Bottom line — The review is a map, not a single ranking A living BMJ review combined **869 randomized trials involving 493,168 adults** with type 2 diabetes. It found no one drug that wins every outcome: cardiovascular risk, kidney disease, weight, hypoglycaemia and adverse effects point toward different choices. > **⚑ Caveat:** This evidence can inform a prescribing conversation; it is not a reason to start, stop or switch medicine without the clinician managing the person's diabetes and other conditions. - **869** — randomized trials - **493,168** — participants - **63** — drugs across 13 classes - **26** — benefit and harm outcomes ### Method — How the evidence network works The review included randomized trials lasting at least 24 weeks. A **network meta-analysis** combines direct head-to-head trials with indirect comparisons through a shared comparator. That allows a broad map, but it also means certainty differs from one comparison to another. The authors used GRADE to rate confidence and a random-effects model to allow for differences across studies. The search for this version ran through 31 July 2024; the project plans updates at least twice a year. ### Benefits — Heart, kidney and weight outcomes do not align perfectly Moderate- to high-certainty evidence confirmed cardiovascular and kidney benefits for **SGLT-2 inhibitors** and **GLP-1 receptor agonists**. **Finerenone** showed benefit for patients who already have chronic kidney disease. The absolute gain varies substantially with a person's baseline cardiovascular and kidney risk. - **Cardiovascular and kidney risk:** SGLT-2 inhibitors and GLP-1 receptor agonists have established benefits; absolute gains are larger when baseline risk is higher. - **Chronic kidney disease:** Finerenone adds evidence for selected patients with established CKD, alongside its potassium risk. - **Weight:** Tirzepatide had the largest average reduction in the network; orforglipron followed, but its evidence was less certain. - **Severe hypoglycaemia:** Sulfonylureas, insulin and DPP-4 inhibitors probably increased risk. - **−8.63 kg** — tirzepatide mean weight difference; moderate certainty - **−7.87 kg** — orforglipron mean difference; low certainty Those weight estimates are averages across a trial network, not forecasts for one person. They also do not settle other priorities such as glucose control, cardiovascular disease, kidney function, tolerability, cost or access. ### Harms — Each class carries a different trade-off - **SGLT-2 inhibitors:** More genital infections (OR 3.29) and diabetic ketoacidosis (OR 2.08); amputations probably increased modestly (OR 1.27). - **Tirzepatide and GLP-1 drugs:** Probably more severe gastrointestinal events; the largest estimate was for tirzepatide (OR 4.21). - **Finerenone:** More severe hyperkalaemia (OR 5.92), making potassium and kidney monitoring relevant. - **Thiazolidinediones:** More major osteoporotic fractures and probably more hospitalization for heart failure. > **i** An odds ratio is a relative measure. It does not say how many additional people will experience an event without the underlying baseline risk. ### Limits — What the review cannot settle - Not every drug pair was compared directly; some estimates come from indirect links in the network. - Trials differed in populations, follow-up and outcome definitions, even though statistical models account for heterogeneity. - Evidence for neuropathy and visual impairment was low or very low certainty. - Whether GLP-1 drugs reduce dementia remained uncertain: OR 0.92, 95% CI 0.83 to 1.02, with low certainty. - The current search cutoff was July 2024, so a living review still requires later updates. > The best-supported choice depends on the outcome a patient most needs to improve and the harm they most need to avoid. ### Next step — Turn the evidence into the right questions For the next clinical review, bring a short list: cardiovascular disease or heart failure, kidney function, desired weight change, previous adverse effects, hypoglycaemia risk, other medicines, cost and access. The review makes those trade-offs easier to discuss; it does not replace individualized care. ## Primary sources - [Telegram post 1438](https://t.me/CNSmydream/1438) - [BMJ paper](https://doi.org/10.1136/bmj-2024-083039) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/40813122/) - [Crossref record](https://api.crossref.org/works/10.1136/bmj-2024-083039) - [PROSPERO CRD42022325948](https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=325948) --- _Published by iyu (https://iyu.app) — the day's AI news, checked against primary sources and rewritten in plain language. Free to quote with attribution and a link to the canonical URL._